RETRACTED: Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend®) on measures of coagulation (Retracted Article)

被引:83
作者
Boldt, J [1 ]
Haisch, G [1 ]
Suttner, S [1 ]
Kumle, B [1 ]
Schellhaass, A [1 ]
机构
[1] Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany
关键词
blood; coagulation; volume replacement; surgery; abdominal;
D O I
10.1093/bja/aef242
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background. Hydroxyethyl starch (HES) may affect blood coagulation. We studied the effects of a modified, balanced, high-molecular weight (mean molecular weight (MW) 550 kDa], high-substituted [degree of substitution (DS) 0.7] HES preparation (Hextend(R)) on coagulation in patients undergoing major abdominal surgery. Methods. Patients were allocated randomly to receive Hextend(R) (n=21), lactated Ringer's solution (RL, n=21) or 6% HES with a low MW (130 kDa) and a low DS (0.4) (n=21). The infusion was started after induction of anaesthesia and continued until the second postoperative day to maintain central venous pressure between 8 and 12 mm Hg. Activated thrombelastography (TEG) was used to assess coagulation. Different activators were used (extrinsic and intrinsic activation of TEG) and aprotinin was added to assess hyperfibrinolytic activity (ApTEG). We measured onset of coagulation [coagulation time (CT=reaction time, r)], the kinetics of clot formation [clot formation time (CFT=coagulation time, k)] and maximum clot firmness (MCF=maximal amplitude, MA). Measurements were performed after induction of anaesthesia, at the end of surgery, 5 h after surgery and on the mornings of the first and second days after surgery. Results. Significantly more HES 130/0.4 [2590 (SD 260) ml] than Hextend(R) [1970 (310) ml] was given. Blood loss was greatest in the Hextend(R) group and did not differ between RL- and HES 130/0.4-treated patients. Baseline TEG data were similar and within the normal range. CT and CFT were greater in the Hextend(R) group immediately after surgery, 5 h after surgery and on the first day than in the two other groups. ApTEG MCF also changed significantly in the Hextend(R) patients, indicating more pronounced fibrinolysis. Volume replacement using RL caused moderate hypercoagulability, shown by a decrease in CT. Conclusion. A modified, balanced high-molecular weight HES with a high degree of substitution (Hextend(R)) adversely affected measures of coagulation in patients undergoing major abdominal surgery, whereas a preparation with a low MW and low DS affected these measures of haemostasis less. Large amounts of RL decreased the coagulation time.
引用
收藏
页码:722 / 728
页数:7
相关论文
共 32 条
[1]   Coagulopathy induced by hydroxyethyl starch [J].
Baldassarre, S ;
Vincent, JL .
ANESTHESIA AND ANALGESIA, 1997, 84 (02) :451-453
[2]   Evaluation of a new hydroxyethyl starch preparation (Hextend(TM)) on selected coagulation parameters [J].
Bick, RL .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1995, 1 (03) :215-229
[3]   RETRACTED: Influence of different volume therapies on platelet function in the critically ill (Retracted Article) [J].
Boldt, J ;
Muller, M ;
Heesen, M ;
Heyn, O ;
Hempelmann, G .
INTENSIVE CARE MEDICINE, 1996, 22 (10) :1075-1081
[4]  
CALATZIS A., 2000, MANAGEMENT BLEEDING, P215
[5]  
Cope JT, 1997, ANN THORAC SURG, V63, P78
[6]   Effects of different plasma substitutes on blood coagulation: A comparative review [J].
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2001, 29 (06) :1261-1267
[7]   Comparison of four methods for the determination of platelet function in whole blood in cardiac surgery [J].
Dietrich, GV ;
Schueck, R ;
Menges, T ;
Kiesenbauer, NP ;
Fruehauf, AC ;
Marquardt, I .
THROMBOSIS RESEARCH, 1998, 89 (06) :295-301
[8]   Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight [J].
Entholzner, EK ;
Mielke, LL ;
Calatzis, AN ;
Feyh, J ;
Hipp, R ;
Hargasser, SR .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2000, 44 (09) :1116-1121
[9]   Hextend®, a physiologically balanced plasma expander for large volume use in major surgery:: A randomized phase III clinical trial [J].
Gan, TJ ;
Bennett-Guerrero, E ;
Phillips-Bute, B ;
Wakeling, H ;
Moskowitz, DM ;
Olufolabi, Y ;
Konstadt, SN ;
Bradford, C ;
Glass, PSA ;
Machin, SJ ;
Mythen, MG .
ANESTHESIA AND ANALGESIA, 1999, 88 (05) :992-998
[10]  
Huet RCGG, 2000, CAN J ANAESTH, V47, P1207